• AAPL 182.69
  • TSLA 177.5383
  • AMZN 187.8099
  • MSFT 410.39
  • INTC 30.8899
  • EURUSD 1.0756
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. RNLX.NASDAQ

Renalytix AI (RNLX NASDAQ) stock market data APIs

$0.7099 0.02(2.9%) as of May 6, 2024

Renalytix AI Financial Data Overview

0.6899
0.7099
-
0.7099
0.67
0.245-4.038
50 893 K
73 769 K
2 410 K
0
1.91
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'RNLX',
Type: 'Common Stock',
Name: 'Renalytix AI',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00VPNC562',
ISIN: NULL,
CUSIP: NULL,
CIK: '1811115',
EmployerIdNumber: NULL,
FiscalYearEnd: 'June',
IPODate: '2020-07-17',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Health Information Services',
HomeCategory: 'ADR',
IsDelisted: false,
}

Renalytix AI Fundamental Data is available in our Financial Data APIs

  • Net Revenue 2 410 K
  • EBITDA -37 790 000
  • Earnings Per Share -0.9
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Renalytix AI Earnings via APIs

  • Latest Release 2024-04-22
  • EPS/Forecast -0.0843

Get Renalytix AI End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Renalytix AI latest news via APIs

New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease

Renalytix plc Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 1...

Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024

Renalytix plc LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimi...
Do you have any questions?
support@eodhistoricaldata.com